Jan Rothuizen

Jan Rothuizen

Auto-generated profile, based on publicly available information

Jan Rothuizen

VIA UC

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2013 in Veterinary Quarterly
Verified
Journal Article
Open access
RFRobert P. Favier
Robert P. Favier
JPJoost H. Poldervaart
Joost H. Poldervaart
TITed S.G.A.M. van Den Ingh
Ted S.G.A.M. van Den Ingh
Louis PenningLouis Penning
Louis Penning
JRJan Rothuizen
Jan Rothuizen
Background: Only one study reports prednisone to prolong survival in dogs with chronic hepatitis irrespective of the causative agent. The aim of this retrospective study was to investigate the effects of prednisolone treatment on survival, clinicopathological variables, and histological grade and stage of idiopathic chronic hepatitis in 36 dogs. Animals and methods: Medical records were reviewed of 36 prednisolone-treated dogs (median age: 8.6 years; range: 2.0–14.6 years) with chronic hepatitis not associated with primary copper accumulation. Clinicopathological results were analyzed pair-wise for 20 dogs, before and after oral prednisolone administration (1 mg/kg BW/day). Dogs were treated for at least 6 weeks, and for an additional 6 weeks if hepatitis was still present at rebiopsy. Follow-up data pertaining to clinical outcome and survival time (Kaplan–Meier estimate procedure) were analyzed. Results: At the follow-up, 11 dogs were in complete remission, 8 dogs had recurrent clinical signs, and 17 dogs had residual disease. Despite treatment, 20 dogs died of hepatitis-related causes. Dogs without cirrhosis survived significantly longer than dogs with cirrhosis. Prednisolone treatment normalized coagulopathies associated with chronic idiopathic hepatitis within one week in all 10 dogs that had coagulopathies at initial diagnosis. Conclusions: Our findings suggest that prednisolone has, in part, beneficial effects on hepatic inflammation and that it may, at least in some cases, limit the progression of fibrosis, which emphasizes the importance of early diagnosis and treatment. We did not see any benefit of prednisolone treatment for dogs with cirrhosis. We could document a highly favorable effect of prednisolone treatment on the coagulopathy associated with canine chronic idiopathic hepatitis.

1 February 2013 in The Veterinary Journal
Verified
Journal Article
Closed access
COC.M.A. Otte
C.M.A. Otte
Louis PenningLouis Penning
Louis Penning
JRJ. Rothuizen
J. Rothuizen
RFR.P. Favier
R.P. Favier

1 December 2011 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
CPChristine Piek
Christine Piek
BBB. Brinkhof
B. Brinkhof
Erik TeskeErik Teske
Erik Teske
JRJ. Rothuizen
J. Rothuizen
ADAldo Dekker
Aldo Dekker
Louis PenningLouis Penning
Louis Penning

1 March 2014 in The Veterinary Journal
Verified
Journal Article
Closed access
HFHille Fieten
Hille Fieten
VBVincent C. Biourge
Vincent C. Biourge
AWAdrian Leslie Watson
Adrian Leslie Watson
PLPeter A.J. Leegwater
Peter A.J. Leegwater
TITed S.G.A.M. van Den Ingh
Ted S.G.A.M. van Den Ingh
JRJan Rothuizen
Jan Rothuizen

1 May 2015 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
HFHille Fieten
Hille Fieten
VBVincent C. Biourge
Vincent C. Biourge
AWAdrian Leslie Watson
Adrian Leslie Watson
PLP.A.J. Leegwater
P.A.J. Leegwater
TIT.S.G.A.M. van Den Ingh
T.S.G.A.M. van Den Ingh
JRJ. Rothuizen
J. Rothuizen
Background: Genetic and environmental factors, including dietary copper intake, contribute to the pathogenesis of copper-associated hepatitis in Labrador retrievers. Clinical disease is preceded by a subclinical phase in which copper accumulates in the liver. Objective: To investigate the effect of a low-copper, high-zinc diet on hepatic copper concentration in Labrador retrievers with increased hepatic copper concentrations. Animals: Twenty-eight clinically healthy, client-owned Labrador retrievers with a mean hepatic copper concentration of 919 ± 477 mg/kg dry weight liver (dwl) that were related to dogs previously diagnosed with clinical copper-associated hepatitis. Methods: Clinical trial in which dogs were fed a diet containing 1.3 ± 0.3 mg copper/Mcal and 64.3 ± 5.9 mg zinc/Mcal. Hepatic copper concentrations were determined in liver biopsy samples approximately every 6 months. Logistic regression was performed to investigate effects of sex, age, initial hepatic copper concentration and pedigree on the ability to normalize hepatic copper concentrations. Results: In responders (15/28 dogs), hepatic copper concentrations decreased from a mean of 710 ± 216 mg/kg dwl copper to 343 ± 70 mg/kg dwl hepatic copper after a median of 7.1 months (range, 5.5–21.4 months). Dogs from a severely affected pedigree were at increased risk for inability to have their hepatic copper concentrations normalized with dietary treatment. Conclusions and Clinical Importance: Feeding a low-copper, high-zinc diet resulted in a decrease in hepatic copper concentrations in a subset of clinically normal Labrador retrievers with previous hepatic copper accumulation. A positive response to diet may be influenced by genetic background. Determination of clinical benefit requires further study.

25 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FSFrank G. van Steenbeek
Frank G. van Steenbeek
LBLindsay Van Den Bossche
Lindsay Van Den Bossche
GGGuy Grinwis
Guy Grinwis
AKAnne Kummeling
Anne Kummeling
IGIngrid H M van Gils
Ingrid H M van Gils
Bart SpeeBart Spee
Bart Spee
Congenital portosystemic shunts are developmental anomalies of the splanchnic vascular system that cause portal blood to bypass the liver. Large-breed dogs are predisposed for intrahepatic portosystemic shunts (IHPSS) and small-breed dogs for extrahepatic portosystemic shunts (EHPSS). While the phenotype resulting from portal bypass of the liver of the two types of shunt is identical, the genotype and molecular pathways involved are probably different. The aim of this study was to gain insight into the pathways involved in the different types of portosystemic shunting. Microarray analysis of mRNA expression in liver tissue from dogs with EHPSS and IHPSS revealed that the expression of 26 genes was altered in either IHPSS or EHPSS samples compared with that in liver samples from control dogs. Quantitative real-time PCR of these genes in 14 IHPSS, 17 EHPSS, and 8 control liver samples revealed a significant differential expression of ACBP, CCBL1, GPC3, HAMP, PALLD, VCAM1, and WEE1. Immunohistochemistry and Western blotting confirmed an increased expression of VCAM1 in IHPSS but its absence in EHPSS, an increased WEE1 expression in IHPSS but not in EHPSS, and a decreased expression of CCBL1 in both shunt types. Regarding their physiologic functions, these findings may indicate a causative role for VCAM1 in IHPSS and WEE1 for IHPSS. CCBL1 could be an interesting candidate to study not yet elucidated aspects in the pathophysiology of hepatic encephalopathy.